<?xml version='1.0' encoding='utf-8'?>
<document id="27548563"><sentence text="Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters."><entity charOffset="8-19" id="DDI-PubMed.27548563.s1.e0" text="gemfibrozil" /></sentence><sentence text="Cytochrome P450 (CYP) 2C8 is a drug metabolizing enzyme of major importance" /><sentence text=" The lipid-lowering drug gemfibrozil has been identified as a strong inhibitor of CYP2C8 in vivo"><entity charOffset="25-36" id="DDI-PubMed.27548563.s3.e0" text="gemfibrozil" /></sentence><sentence text=" This effect is due to mechanism-based inhibition of CYP2C8 by gemfibrozil 1-O-β-glucuronide"><entity charOffset="63-92" id="DDI-PubMed.27548563.s4.e0" text="gemfibrozil 1-O-β-glucuronide" /></sentence><sentence text=" In vivo, gemfibrozil is a fairly selective CYP2C8 inhibitor, which lacks significant inhibitory effect on other CYP enzymes"><entity charOffset="10-21" id="DDI-PubMed.27548563.s5.e0" text="gemfibrozil" /></sentence><sentence text=" Gemfibrozil can, however, have a smaller but clinically meaningful inhibitory effect on membrane transporters, such as organic anion transporting polypeptide 1B1 and organic anion transporter 3"><entity charOffset="1-12" id="DDI-PubMed.27548563.s6.e0" text="Gemfibrozil" /></sentence><sentence text=" Areas covered: This review describes the inhibitory effects of gemfibrozil on CYP enzymes and membrane transporters"><entity charOffset="64-75" id="DDI-PubMed.27548563.s7.e0" text="gemfibrozil" /></sentence><sentence text=" The clinical drug interactions caused by gemfibrozil and the different mechanisms contributing to the interactions are reviewed in detail"><entity charOffset="42-53" id="DDI-PubMed.27548563.s8.e0" text="gemfibrozil" /></sentence><sentence text=" Expert opinion: Gemfibrozil is a useful probe inhibitor of CYP2C8 in vivo, but its effect on membrane transporters has to be taken into account in study design and interpretation"><entity charOffset="17-28" id="DDI-PubMed.27548563.s9.e0" text="Gemfibrozil" /></sentence><sentence text=" Moreover, gemfibrozil could be used to boost the pharmacokinetics of CYP2C8 substrate drugs"><entity charOffset="11-22" id="DDI-PubMed.27548563.s10.e0" text="gemfibrozil" /></sentence><sentence text=" Identification of gemfibrozil 1-O-β-glucuronide as a potent mechanism-based inhibitor of CYP2C8 has led to recognition of glucuronide metabolites as perpetrators of drug-drug interactions"><entity charOffset="19-48" id="DDI-PubMed.27548563.s11.e0" text="gemfibrozil 1-O-β-glucuronide" /><entity charOffset="123-134" id="DDI-PubMed.27548563.s11.e1" text="glucuronide" /><pair ddi="false" e1="DDI-PubMed.27548563.s11.e0" e2="DDI-PubMed.27548563.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27548563.s11.e0" e2="DDI-PubMed.27548563.s11.e1" /></sentence><sentence text=" Recently, also acyl glucuronide metabolites of clopidogrel and deleobuvir have been shown to strongly inhibit CYP2C8"><entity charOffset="16-32" id="DDI-PubMed.27548563.s12.e0" text="acyl glucuronide" /><entity charOffset="48-59" id="DDI-PubMed.27548563.s12.e1" text="clopidogrel" /><entity charOffset="64-74" id="DDI-PubMed.27548563.s12.e2" text="deleobuvir" /><pair ddi="false" e1="DDI-PubMed.27548563.s12.e0" e2="DDI-PubMed.27548563.s12.e0" /><pair ddi="false" e1="DDI-PubMed.27548563.s12.e0" e2="DDI-PubMed.27548563.s12.e1" /><pair ddi="false" e1="DDI-PubMed.27548563.s12.e0" e2="DDI-PubMed.27548563.s12.e2" /><pair ddi="false" e1="DDI-PubMed.27548563.s12.e1" e2="DDI-PubMed.27548563.s12.e1" /><pair ddi="false" e1="DDI-PubMed.27548563.s12.e1" e2="DDI-PubMed.27548563.s12.e2" /></sentence><sentence text="" /></document>